Persistence Capital Partners, a Canadian healthcare services investment firm, appointed Lloyd M. Segal as a Partner of the Fund. Segal was previously CEO of Thallion Pharmaceuticals, where he currently serves as Chairman.
Persistence Capital Partners (“PCP”), a leading Canadian healthcare services investor, today announced the appointment of Lloyd M. Segal as a Partner of the Fund.
Lloyd has held several CEO roles in the Biotechnology industry, and has served on the Boards of numerous public and private healthcare companies in North America. Most recently, Lloyd was the CEO of Thallion Pharmaceuticals, where he currently serves as Chairman. He is also a member of the Boards of Biovail Corporation and GBC North America Fund, and was previously a consultant with McKinsey & Co. He earned a B.A. from Brandeis University and an MBA from Harvard University, Graduate School of Business.
Mr. Segal will lead new investments by PCP, and support and advise the management of existing portfolio companies.
About Persistence Capital Partners (PCP)
PCP is a private equity fund concentrating on high-growth opportunities in healthcare. With its deep industry expertise, PCP aims to create long term capital appreciation by identifying and developing attractive healthcare investments, with a focus on services businesses across the sector.